FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310127232> ?p ?o ?g. }

• W4310127232 endingPage "11855" @default.
• W4310127232 startingPage "11854" @default.
• W4310127232 abstract "Introduction The novel pediatric-like and TKI-based induction regimens induce up to 90 % of complete hematologic response in, respectively, Ph'-negative and Ph'-positive B-Cell Acute Lymphoblastic Leukemia (B-ALL). Minimal residual disease (MRD) strongly correlates with relapse and clearance of MRD is the goal of treatment. Blinatumomab is a bispecific T-cell engager that redirects T-Cells to kill CD19+ cells. Data from clinical trials show that the MRD-positive patients responding to Blinatumomab achieve a better survival than the non-responsive. This retrospective study from real-life demonstrates a superior outcome for MRD-responsive patients to blinatumomab over non-responsive patients. Patients and methods Data from adults treated with blinatumomab in six centers were analyzed to identify factors correlated to survival. Each cycle of blinatumomab was administered in 4 weeks at 15 mg/m2/day by continuous infusion followed by a 2-week interval. Intrathecal prophylaxis with ARA-C, Methotrexate and Dexamethasone was performed between cycles. Twenty-nine (87 %) patients received levetiracetam for seizure-prophylaxis. MRD was measured after each cycle by RT-qPCR with a sensitivity of 10-4 for clonal IgH and for BCR-ABL. As MRD response was considered clonal IgH or BCR-ABL < 10-4. Relapse-free survival (RFS) and overall survival (OS) were estimated by the Kaplan-Meier analysis and compared by the log-rank across the sub-groups using 95 % confidence intervals. The significant variables were compared in multivariate analysis by the log-logistic regression model. Toxicity was graded according to CTCAEs v.4 scale. Results From January 2016 to February 2021 34 B-ALL patients received Blinatumomab. The median age was 37 (18-72). Male to female ratio was 14/20. B-ALL was Ph'+ in 9 and Ph'- in 25 patients, respectively. Indications to blinatumomab were, respectively, relapsed/refractory B-ALL in 19 and MRD-positive in 15 patients. SNC disease was negative before blinatumomab in all patients. Blinatumomab was administered, respectively, as 2nd line in 26 and as > 2nd line of therapy in 8 patients. Overall, 24 patients received hematopoietic transplantation (HCT): 10 before and 14 after blinatumomab, respectively. The cycles of blinatumomab were 1, 2, 3 and 4, respectively, in 10, 13, 5, and 5 patients. The response to blinatumomab was, respectively, complete remission without MRD in 17 (50 %), complete remission with MRD in 8 (23 %), refractory in 4 (12 %) and extramedullary progression in 2 (6 %) patients. Three patients (9 %) had to suspend treatment in 1st cycle because of grade III-IV neuro-toxicity. The response was obtained after 1 and 2 cycles in 18 (72 %) and 7 patients (28 %), respectively. Among the MRD-responsive, MRD-negativity was obtained after 1 and 2 cycles in 16 (93 %) and 1 (7 %) patient, respectively. At a median follow-up of 16 months (1-47) 15 patients (44 %) had relapsed, 15 (44 %) were alive and in complete remission and 4 (12 %) died of transplant-related mortality. The median RFS was 12.5 months (1-39). The median OS was 15.5 months (1-46). The median RFS was 21 vs 4.4 months among MRD-responsive and non-responsive patients, respectively (p = .0004). The median OS was 27 vs 8.7 months among MRD-responsive and non-responsive patients, respectively (p = .008). Apart from MRD-response, the other variables significant for RFS were: blinatumomab as ≤ 2nd line (p = .0008), blinatumomab administered pre-HCT (p = .002) and MRD as an indication to treatment (p = .001). Apart from MRD-response, the other variable significant for OS was MRD as an indication (p = .01). By multivariate analysis only the MRD-response resulted significant for RFS (p = .0009) and OS (p = .02). MRD-response resulted significantly for RFS and OS also by censoring at HCT (p < .0001 and .005, respectively) [Figure 1]. Clinically significant toxicity was: grade II cytokine-release syndrome in 2 patients, grade III and IV neuro-toxicity in 2 and 1 patient, respectively. Overall, the percentage of patients experiencing grade III-IV neuro-toxicity, which occurred in 1st cycle, was 9 %. Conclusion This retrospective study in adult B-ALL Ph'- and Ph'+ patients, confirms the ability of blinatumomab to reach the MRD-negativity in a substantial proportion of patients. MRD-responsive gain a significant survival advantage over non-responsive patients. This advantage was observed both for transplanted and non-transplanted patients. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal" @default.
• W4310127232 created "2022-11-30" @default.
• W4310127232 creator A5000098294 @default.
• W4310127232 creator A5001923523 @default.
• W4310127232 creator A5003232812 @default.
• W4310127232 creator A5006314162 @default.
• W4310127232 creator A5011614506 @default.
• W4310127232 creator A5014501048 @default.
• W4310127232 creator A5016021915 @default.
• W4310127232 creator A5019674488 @default.
• W4310127232 creator A5022126213 @default.
• W4310127232 creator A5026122857 @default.
• W4310127232 creator A5034992947 @default.
• W4310127232 creator A5058760899 @default.
• W4310127232 creator A5062195312 @default.
• W4310127232 creator A5072927664 @default.
• W4310127232 creator A5076867656 @default.
• W4310127232 creator A5084615391 @default.
• W4310127232 creator A5088942860 @default.
• W4310127232 date "2022-11-15" @default.
• W4310127232 modified "2023-10-17" @default.
• W4310127232 title "Minimal Residual Disease Negativity after Blinatumomab Is Predictive of Survival in B-Cell Acute Lymphoblastic Leukemia: Data from a Real-Life Study" @default.
• W4310127232 doi "https://doi.org/10.1182/blood-2022-166546" @default.
• W4310127232 hasPublicationYear "2022" @default.
• W4310127232 type Work @default.
• W4310127232 citedByCount "0" @default.
• W4310127232 crossrefType "journal-article" @default.
• W4310127232 hasAuthorship W4310127232A5000098294 @default.
• W4310127232 hasAuthorship W4310127232A5001923523 @default.
• W4310127232 hasAuthorship W4310127232A5003232812 @default.
• W4310127232 hasAuthorship W4310127232A5006314162 @default.
• W4310127232 hasAuthorship W4310127232A5011614506 @default.
• W4310127232 hasAuthorship W4310127232A5014501048 @default.
• W4310127232 hasAuthorship W4310127232A5016021915 @default.
• W4310127232 hasAuthorship W4310127232A5019674488 @default.
• W4310127232 hasAuthorship W4310127232A5022126213 @default.
• W4310127232 hasAuthorship W4310127232A5026122857 @default.
• W4310127232 hasAuthorship W4310127232A5034992947 @default.
• W4310127232 hasAuthorship W4310127232A5058760899 @default.
• W4310127232 hasAuthorship W4310127232A5062195312 @default.
• W4310127232 hasAuthorship W4310127232A5072927664 @default.
• W4310127232 hasAuthorship W4310127232A5076867656 @default.
• W4310127232 hasAuthorship W4310127232A5084615391 @default.
• W4310127232 hasAuthorship W4310127232A5088942860 @default.
• W4310127232 hasBestOaLocation W43101272321 @default.
• W4310127232 hasConcept C11413529 @default.
• W4310127232 hasConcept C126322002 @default.
• W4310127232 hasConcept C143998085 @default.
• W4310127232 hasConcept C155512373 @default.
• W4310127232 hasConcept C2778020697 @default.
• W4310127232 hasConcept C2778461978 @default.
• W4310127232 hasConcept C2779823535 @default.
• W4310127232 hasConcept C2781107101 @default.
• W4310127232 hasConcept C2909962599 @default.
• W4310127232 hasConcept C41008148 @default.
• W4310127232 hasConcept C71924100 @default.
• W4310127232 hasConceptScore W4310127232C11413529 @default.
• W4310127232 hasConceptScore W4310127232C126322002 @default.
• W4310127232 hasConceptScore W4310127232C143998085 @default.
• W4310127232 hasConceptScore W4310127232C155512373 @default.
• W4310127232 hasConceptScore W4310127232C2778020697 @default.
• W4310127232 hasConceptScore W4310127232C2778461978 @default.
• W4310127232 hasConceptScore W4310127232C2779823535 @default.
• W4310127232 hasConceptScore W4310127232C2781107101 @default.
• W4310127232 hasConceptScore W4310127232C2909962599 @default.
• W4310127232 hasConceptScore W4310127232C41008148 @default.
• W4310127232 hasConceptScore W4310127232C71924100 @default.
• W4310127232 hasIssue "Supplement 1" @default.
• W4310127232 hasLocation W43101272321 @default.
• W4310127232 hasOpenAccess W4310127232 @default.
• W4310127232 hasPrimaryLocation W43101272321 @default.
• W4310127232 hasRelatedWork W2547353143 @default.
• W4310127232 hasRelatedWork W2576962736 @default.
• W4310127232 hasRelatedWork W2593458633 @default.
• W4310127232 hasRelatedWork W2955874201 @default.
• W4310127232 hasRelatedWork W2988903265 @default.
• W4310127232 hasRelatedWork W3016714707 @default.
• W4310127232 hasRelatedWork W3039690284 @default.
• W4310127232 hasRelatedWork W3096871612 @default.
• W4310127232 hasRelatedWork W3133548585 @default.
• W4310127232 hasRelatedWork W4281551859 @default.
• W4310127232 hasVolume "140" @default.
• W4310127232 isParatext "false" @default.
• W4310127232 isRetracted "false" @default.
• W4310127232 workType "article" @default.